title: [Effect of atorvastatin on carotid intima-medial of thickness of primary hypertension patients of Han nationality in China].
abstract: OBJECTIVE
  To investigate the efficacy of 10 mg or 20 mg atorvastatin + long acting antihypertensive in carotid intima-medial thickness (IMT).
  
  
  METHODS
  151 patients of Han nationality in South China with mild hypertensive were randomly divided into 3 groups: atorvastatin 10 mg group (n = 50) receive 10 mg atorvastatin and amlodipine + benazepril; atorvastatin 20 mg group (n = 61) receive 20 mg atorvastatin and amlodipine + benazepril; the control group (n = 40) receive amlodipine + benazepril. The patients were detected IMT, vascular function, lipids and inflammatory factor in pretherapy and every 3 months.
  
  
  RESULTS
  atorvastatin 10 mg or 20 mg groups have significantly change contrast to control group: (1) IMT was decreased (P < 0.01). (2) Deltadia-P% and Deltadia-N% were increased (P < 0.01). (3) LDL-C level was decreased by 30% in a atorvastatin 10 mg group and 40.48% in 20 mg group respectively (P < 0.01).
  
  
  CONCLUSIONS
  Atorvastatin delays the development of atherosclerosis in hypertensive patients, improves endothelial function, and strengthens the effect of lipid-lowering.
authors.affiliation: Department of Neurology, First Affiliated Hospital of Fujian Medical University, Fuzhou 350005, China.
authors.forename: Jing
authors.initials: J
authors.lastname: Wu
authors.forename: Gang
authors.initials: G
authors.lastname: Wu
authors.forename: Mei-ping
authors.initials: MP
authors.lastname: Wang
authors.forename: Dong-lin
authors.initials: DL
authors.lastname: Liu
authors.forename: Zhi-jian
authors.initials: ZJ
authors.lastname: Hu
authors.forename: Guo-ying
authors.initials: GY
authors.lastname: Xu
mesh_terms: D000368:Aged; D017311:Amlodipine / Q000627:therapeutic use; D000924:Anticholesteremic Agents / Q000627:therapeutic use*; D000959:Antihypertensive Agents / Q000627:therapeutic use; D000069059:Atorvastatin; D001552:Benzazepines / Q000627:therapeutic use; D002339:Carotid Arteries / Q000187:drug effects* / Q000473:pathology; D002681:China; D008078:Cholesterol, LDL / Q000097:blood; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D004730:Endothelium, Vascular / Q000187:drug effects / Q000503:physiopathology; D005260:Female; D006538:Heptanoic Acids / Q000627:therapeutic use*; D006801:Humans; D006973:Hypertension / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D011758:Pyrroles / Q000627:therapeutic use*; D013997:Time Factors; D016896:Treatment Outcome; D017539:Tunica Intima / Q000187:drug effects / Q000473:pathology; D017540:Tunica Media / Q000187:drug effects / Q000473:pathology
chemical_list: D000924:Anticholesteremic Agents; D000959:Antihypertensive Agents; D001552:Benzazepines; D008078:Cholesterol, LDL; D006538:Heptanoic Acids; D011758:Pyrroles; D017311:Amlodipine; D000069059:Atorvastatin; C044946:benazepril